An official website of the United States government
NIH Websites Are Changing Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Trial Status: active
This study will assess the safety and efficacy of VS-7375 alone in patients with
metastatic KRAS G12D-mutated Non-Small Cell Lung Cancer
Inclusion Criteria
Received at least 1 and no more than 2 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC. Patients with 2L-4L with brain metastases:
Adequate organ function
ECOG PS=0 or 1
Received at least 1 and no more than 3 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.
Have asymptomatic and untreated brain metastases
Received prior treatment with a platinum-based chemotherapy regimen and an immune checkpoint inhibitor in the advanced, non-resectable setting.
Histopathology confirmed unresectable locally advanced or metastatic NSCLC
At least 1 untreated measurable brain lesion per mRECIST v1.1 with a long axis ≥ 0.5 cm and ≤ 3 cm.
Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
Measurable disease per RECIST 1.1
Have documented disease progression during or following their most recent prior line of therapy. Patients with 2L/3L on stable or preferred dose:
Exclusion Criteria
Other protocol-defined inclusion/exclusion criteria may apply
Radiation therapy (RT) within 1 week of first treatment dose
Receipt of strong CYP3A4 inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter
Receipt of PPI or H2 blocker within 5 days
Receipt of prior direct RAS inhibitor
Have any other documented co-existing common RAS mutation(s)
Untreated or symptomatic CNS metastasis
History of drug-induced Interstitial Lung Disease
Inability to swallow oral medication
Major surgery within 4 weeks of first treatment dose
Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07659782.
Locations matching your search criteria
United States
Colorado
Aurora
UCHealth University of Colorado Hospital
Status: Active
Name Not Available
Florida
Tampa
Moffitt Cancer Center
Status: Active
Name Not Available
Georgia
Atlanta
Emory University Hospital/Winship Cancer Institute
Status: Active
Name Not Available
Illinois
Chicago
University of Chicago Comprehensive Cancer Center
Status: Active
Name Not Available
New York
New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone